全球双特异性抗体市场机会、剂量、专利、定价、销售和临床试验展望（2031 年）

全球双特异性抗体市场机会、剂量、专利、定价、销售和临床试验展望（2031 年）报告的主要发现和亮点：

• 已通过核准的双特异性抗体数量：18
• 按全球和区域边界分析年度和季度销售额
• 全球双特异性抗体市场机会：到2031年超过600亿美元
• 2025年全球双特异性抗体市场规模：超过160亿美元
• 深入了解已通过核准的抗体剂量、专利、定价和销售情况。
• 对双特异性抗体专有平台的深入了解：超过 30 个平台
• 对临床试验中超过 550 种双特异性抗体的全面深入了解
• 全球双特异性抗体临床试验依公司、适应症及分期划分。

双特异性抗体的必要性及本报告的意义

双特异性抗体处于免疫疗法和标靶治疗创新发展的前沿，因为它们有望更有效地应对疾病的复杂性。随着癌症治疗中肿瘤异质性、讯号通路冗余和治疗抗药性等挑战不断限制单药疗法的潜力，对双特异性抗体疗法的需求日益增长。

近年来，双特异性抗体在医药市场取得了显着成长，尤其是在癌症治疗领域，它们利用免疫系统攻击癌细胞展现出巨大的潜力。除了癌症之外，双特异性抗体还在包括自体免疫疾病在内的广泛领域进行评估。

全球双特异性抗体市场预计2025年将达到约169亿美元，其中美国占市场主导地位，占总销售额的60%以上。目前已有18种双特异性抗体获批上市，另有多种新药候选药物正在核准监管批准，在临床进展稳步推进和行业持续投资的支持下，该市场正朝着商业性成熟迈进。因此，本报告对于希望在这个不断成长的市场中取得成功的製药公司、投资者和其他相关人员而言，都是一份极具价值的资讯来源。

报告中包含对临床试验的深入分析

临床试验在双特异性抗体疗法的研发中发挥了核心作用。尤其是在肿瘤学领域，许多针对不同适应症的双特异性抗体正在进行临床试验，其作为骨髓恶性肿瘤和固体癌（例如非小细胞肺癌（NSCLC）和结直肠癌（CRC））治疗药物的潜力正在接受评估。

本报告对临床试验进行了系统性全面的分析，涵盖了从初步人体试验到确证性后期临床试验的各个阶段。我们的分析重点在于针对復发或难治性患者群体的研究，在这些研究中，双特异性抗体已展现出令人鼓舞的疗效。此外，我们也分析了研究设计、患者选择标准、给药策略和联合治疗。临床策略的一个新趋势是探索双特异性抗体在肿瘤学以外的领域（例如自体免疫疾病和发炎性疾病）的应用，从而扩大其潜在应用范围。双特异性抗体进入后期研发阶段和提交监管申请的进展表明，人们对这类药物的信心日益增强。

专注于双特异性抗体研发的主要企业

双特异性抗体市场竞争异常激烈，既有老牌製药公司，也有新兴生技公司积极进军该市场。强生、安进、Genmab 和罗氏等领导企业凭藉着雄厚的财力、卓越的研发实力和稳固的肿瘤业务基础，始终处于市场前沿。这些公司不断拓展其双特异性抗体产品线，涵盖多个疾病领域，不仅巩固了自身市场地位，也扩大了在该类药物中的市场份额。同时，为了维持市场竞争力，它们也持续进行产品组合多元化。

同时，Invenra、Biosion 和 Alligator Bioscience 等新兴生技公司也为该市场的发展做出了重要贡献。这些公司不断推出差异化的双特异性抗体和新的潜在适应症，进一步活性化了市场竞争。

技术平台、合作伙伴关係和协议

技术创新是双特异性抗体研发的核心。目前已开发出多种专有技术，用于优化双特异性抗体的结合特异性、稳定性、生产流程和治疗效果。这些技术包括双特异性抗体末端连接酶（BiTE）、双可变区域以及其他双特异性抗体形式。

此外，合作关係和授权协议是加速研发进程和拓展临床效用的关键要素。这些合作关係使各机构能够充分利用彼此的专业知识，分担研发风险，并加强全球商业化。艾伯维与瑞创生物就RC148达成的协议就是一个绝佳的例子，它展现了策略合作如何推动下一代双特异性抗体（尤其是联合治疗）的创新。

一份概述双特异性抗体片段未来发展方向的报告。

在乐观的预测下，双特异性抗体市场预计未来将持续成长。这一市场成长预计将受到该领域临床、技术和治疗进展的推动。越来越多的后期临床试验表明，预计未来将有更多双特异性抗体获得监管部门的核准。这将进一步巩固双特异性抗体在现代医学中的地位。

联合治疗有望在未来推动双特异性抗体的广泛应用。这一点在肿瘤治疗领域尤其明显，双特异性抗体有望在与其他药物的联合治疗中发挥至关重要的作用。此外，双特异性抗体的进步预计在不久的将来带来更好的临床疗效。

除了在肿瘤治疗领域的应用外，双特异性抗体也在自体免疫疾病和发炎性疾病领域进行研究。凭藉着积极的投资和策略合作，双特异性抗体有望在推动各疾病领域下一代治疗方法的研发中发挥关键作用。

目录

第一章：调查方法

第二章：二价抗体概述

第三章：双特异性抗体的联合治疗策略

• 化疗
• 标靶治疗
• 免疫疗法
• 放射线治疗

第四章：关于市售已通过核准特异性抗体的考量

• 公司名称、适应症、所在地和作用机制
• 双特异性抗体将被授予监管认定。

第五章：双特异性抗体的独特平台

第六章：双特异性抗体市场的全球与区域展望

• 年度和季度销售趋势（2020-2025 年）
• 关于已通过核准的双特异性抗体的报销和保险覆盖范围的政策
• 全球双特异性抗体市场预测（至2031年）

第七章：全球双特异性抗体市场趋势（按地区划分）

• 我们
• 欧洲
• 中国
• 英国
• 日本
• 韩国
• 澳洲
• 加拿大
• 拉丁美洲

第八章：已通过核准的双特异性抗体－临床、专利、定价和行销见解

• 布林奇特
• 亨利布拉
• 利维凡特
• 瓦比斯莫
• 伦苏米奥
• 凯塔尼
• 特克瓦伊里
• 科尔姆维
• 埃普金利
• 塔尔拜
• 艾瑞克斯菲奥
• 伊姆德托拉
• 伊沃内西单抗
• 老斯波诺
• 吉赫拉
• 比曾格里
• 科尔朱尼
• 淋巴系统

第九章：全球双特异性抗体临床试验（按公司、适应症和阶段划分）

• 研究
• 临床前
• 第一阶段
• 第一/二期
• 第二阶段
• 第二阶段
• 第二/三期
• 第三阶段
• 预註册
• 挂号的

第十章：市售双特异性抗体的临床研究结果（依公司、国家及适应症划分）

第十一章：按适应症分類的双特异性抗体全球调查及市场趋势

• 癌症
  • 骨髓恶性肿瘤
  • 固体癌
• 自体免疫疾病与发炎性疾病
• 血液疾病
• 眼科疾病
• 微生物疾病

第十二章 竞争格局

• AbbVie
• ABL Bio
• Abzyme Therapeutics
• Affimed Therapeutics
• Akeso Biopharma
• Alligator Bioscience
• Alphamab Oncology
• Amgen
• Antibody Therapeutics
• APITBIO
• Aptevo Therapeutics
• Astellas Pharma
• AstraZeneca
• BeOne Medicines
• BioAtla
• BioNTech
• Biosion
• BJ Bioscience
• EpimAb Biotherapeutics
• FutureGen Biopharmaceutical
• Genentech
• Genmab
• Gensun Biopharma
• Harbour BioMed
• ImmuneOnco Biopharma
• Innovent Biologics
• Invenra
• Jazz Pharmaceuticals
• Johnson & Johnson
• Kenjockety Biotechnology
• LaNova Medicines Limited
• Light Chain Bioscience
• Lindis Biotech
• Linton Pharm
• Lyvgen Biopharma
• MacroGenics
• Merus
• NovaBridge Biosciences
• NovaRock Biotherapeutics
• Novo Nordisk
• Pfizer
• Phanes Therapeutics
• Prestige BioPharma
• Regeneron Pharmaceuticals
• Revitope
• Roche
• Summit Therapeutics
• Virtuoso Therapeutics
• Xencor
• Zymeworks

Global Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031 Report Findings & Highlights:

• Number Of Approved Bispecific Antibodies: 18
• Global, Regional Annual & Quarterly Sales Insight
• Global Bispecific Antibodies Market Opportunity: > USD 60 Billion By 2031
• Global Bispecific Antibodies Market In 2025: > USD 16 Billion
• Approved Antibodies Dosage, Patent, Pricing & Sales Insight
• Insight On Bispecific Antibodies Proprietary Platforms: >30 Platforms
• Comprehensive Insight On More than 550 Bispecific Antibodies In Clinical Trials
• Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

Need For Bispecific Antibodies & Why This Report?

Bispecific antibodies have been at the forefront of revolutionizing the horizon of immunotherapy and targeted therapy due to their potential to address the complexities of disease more effectively. With the persistence of challenges in cancer therapy, tumor heterogeneity, pathway redundancy, and treatment resistance limiting the full potential of single-agent therapy, there is a growing need for bispecific antibody therapeutics.

In the recent years, bispecific antibodies have witnessed substantial growth in the pharmaceutical market, especially in cancer therapy, where they have been shown to have substantial potential in harnessing the immune system to fight cancer. Apart from cancer, bispecific antibodies have also been evaluated for autoimmune diseases and beyond.

The global bispecific antibody market was estimated to be around US$ 16.9 Billion in 2025, with the US dominating the market, representing more than 60% of the total sales. With 18 bispecific antibodies already approved and regulatory filings for additional candidates in progress, the market is transitioning toward commercial maturity, supported by strong clinical progress and continued industry investment. This report, thus, serves as a valuable asset to pharmaceutical companies, investors and other stakeholders seeking realization in this continuously expanding market

Clinical Trials Insight Included In Report

Clinical trials have been at the core of bispecific antibody therapeutics development. With a large pipeline of bispecific antibodies under clinical investigation for various indications, particularly in oncology, bispecific antibodies are being evaluated for their potential to treat hematological malignancies and solid tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

The report undertakes a systematic and comprehensive analysis of clinical trials, covering first-in-human studies to confirmatory late-stage studies. Our analysis includes trial design, patient selection criteria, dose strategies, combination therapies, as well as special focus on studies conducted on relapsed or refractory patient populations, where bispecific antibodies have shown promising results. The emerging trends in clinical strategies are also exploring bispecific antibodies beyond oncology to other diseases such as autoimmune and inflammatory diseases, thereby expanding the potential application of bispecific antibodies. The progress of bispecific antibodies to late-stage development and regulatory submissions underscores the growing confidence in this class of drugs.

Major Companies Active In R&D Of Bispecific Antibodies

The bispecific antibody market has a competitive environment that is influenced by the active participation of both established pharmaceutical players as well as emerging biotechnology players. Established players such as JNJ, Amgen, Genmab and Roche are still at the forefront, backed by their financial capabilities, development expertise, as well as their existing oncology franchise. These players are continually expanding their bispecific antibody pipeline across various diseases, thereby not only strengthening their position but also expanding their presence in this class of drugs. However, they are also continuously diversifying their portfolios to remain competitive in the market.

On the other hand, emerging biotechnology players, such as Invenra, Biosion and Alligator Bioscience, are significantly contributing to the development of this market. These players are continuously entering this market with differentiated bispecific antibodies as well as novel potential applications, thereby adding to the competitive environment.

Technology Platforms, Collaborations & Agreements

Technological innovation is at the heart of bispecific antibody development. Various proprietary technologies have been developed to optimize bispecific antibody binding specificity, stability, manufacturability, and therapeutic efficacy. This includes formats such as BiTEs, dual variable domains, and other bispecific antibody formats.

Additionally, collaborations and licensing deals are an important factor in accelerating development pathways and expanding clinical utility. Such collaborations allow organizations to leverage mutual expertise and share developmental risks while improving global commercialization efforts. The Abbvie and RemeGen deal for RC148 is an excellent example of how strategic collaborations are driving innovation in next-generation bispecific antibodies, particularly in combination therapies.

Report Indicating Future Direction Of Bispecific Antibody Segment

The bispecific antibody market is expected to grow in the future with an optimistic outlook. The growth in this market is expected to be driven by clinical, technological, and therapeutic advances in the field. The increasing number of clinical trials in late stages suggests that more bispecific antibodies are expected to receive regulatory approval in the near future. This would further cement the position of bispecific antibodies in modern medicine.

Combination approach is expected to play an important role in driving bispecific antibodies in the future. This is particularly true in oncology indications where bispecific antibodies are expected to play an important part in combination therapies with other drugs. In addition to this, advances in bispecific antibodies are expected to drive better clinical outcomes in the near future.

In addition to oncology indications, bispecific antibodies are also being explored in autoimmune and inflammatory diseases. In conjunction with strong investment activity and strategic collaborations, bispecific antibodies are expected to play an important role in driving next-generation therapies in various disease indications.

Table of Contents

1. Reserch Methodology

2. Introduction To Bispecific Antibodies

3. Bispecific Antibody Combination Strategies

• 3.1 Chemotherapy
• 3.2 Targeted Therapy
• 3.3 Immunotherapy
• 3.4 Radiotherapy

4. Commercially Approved Bispecific Antibodies Insight

• 4.1 Company, Indication, Location & MOA
• 4.2 Bispecific Antibodies Granted Regulatory Designations

5. Bispecific Antibodies Proprietary Platforms

6. Global & Regional Bispecific Antibody Market Outlook

• 6.1 Yearly & Quarterly Sales Insight (2020 To 2025)
• 6.2 Approved Bispecific Antibodies Reimbursement & Coverage Policy
• 7.10 Global Bispecific Antibody Market Forecast 2031

7. Global Bispecific Antibody Market Trends By Region

• 7.1 US
• 7.2 Europe
• 7.3 China
• 7.4 UK
• 7.5 Japan
• 7.6 South Korea
• 7.7 Australia
• 7.8 Canada
• 7.9 Latin America

8. Approved Bispecific Antibodies - Clinical, Patent, Pricing & Sales Insight

• 8.1 Blincyto
• 8.2 Hemlibra
• 8.3 Rybrevant
• 8.4 Vabysmo
• 8.5 Lunsumio
• 8.6 Kaitani
• 8.7 Tecvayli
• 8.8 Columvi
• 8.9 Epkinly
• 8.10 Talvey
• 8.11 Elrexfio
• 8.12 Imdelltra
• 8.13 Ivonescimab
• 8.14 Ordspono
• 8.15 Ziihera
• 8.16 Bizengri
• 8.17 Korjuny
• 8.18 Lynozyfic

9. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

• 9.1 Research
• 9.2 Preclinical
• 9.3 Phase I
• 9.4 Phase I/II
• 9.5 Phase II
• 9.6 Phase II
• 9.7 Phase-II/III
• 9.8 Phase III
• 9.9 Preregistration
• 9.10 Registered

10. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

11. Global Bispecific Antibodies Research & Market Trends By Indications

• 11.1 Cancer
  • 11.1.1 Hematological Malignancies
  • 11.1.2 Solid Cancers
• 11.2 Autoimmune & Inflammatory Diseases
• 11.3 Blood Disorders
• 11.4 Ocular Diseases
• 11.5 Microbial Diseases

12. Competitive Landscape

• 12.1 AbbVie
• 12.2 ABL Bio
• 12.3 Abzyme Therapeutics
• 12.4 Affimed Therapeutics
• 12.5 Akeso Biopharma
• 12.6 Alligator Bioscience
• 12.7 Alphamab Oncology
• 12.8 Amgen
• 12.9 Antibody Therapeutics
• 12.10 APITBIO
• 12.11 Aptevo Therapeutics
• 12.12 Astellas Pharma
• 12.13 AstraZeneca
• 12.14 BeOne Medicines
• 12.15 BioAtla
• 12.16 BioNTech
• 12.17 Biosion
• 12.18 BJ Bioscience
• 12.19 EpimAb Biotherapeutics
• 12.20 FutureGen Biopharmaceutical
• 12.21 Genentech
• 12.22 Genmab
• 12.23 Gensun Biopharma
• 12.24 Harbour BioMed
• 12.25 ImmuneOnco Biopharma
• 12.26 Innovent Biologics
• 12.27 Invenra
• 12.28 Jazz Pharmaceuticals
• 12.29 Johnson & Johnson
• 12.30 Kenjockety Biotechnology
• 12.31 LaNova Medicines Limited
• 12.32 Light Chain Bioscience
• 12.33 Lindis Biotech
• 12.34 Linton Pharm
• 12.35 Lyvgen Biopharma
• 12.36 MacroGenics
• 12.37 Merus
• 12.38 NovaBridge Biosciences
• 12.39 NovaRock Biotherapeutics
• 12.40 Novo Nordisk
• 12.41 Pfizer
• 12.42 Phanes Therapeutics
• 12.43 Prestige BioPharma
• 12.44 Regeneron Pharmaceuticals
• 12.45 Revitope
• 12.46 Roche
• 12.47 Summit Therapeutics
• 12.48 Virtuoso Therapeutics
• 12.49 Xencor
• 12.50 Zymeworks

List of Figures

• Figure 2-1: Bispecific Antibodies - Advantages
• Figure 3-1: Antibody-Chemotherapy Combination - Advantages
• Figure 3-2: Antibody-Chemotherapy Combination - Impending Challenges
• Figure 4-1: Blincyto - Mechanism Of Action
• Figure 4-2: Hemlibra - Mechanism Of Action
• Figure 4-3: Rybrevant - Mechanism Of Action
• Figure 4-4: Tecvayli - Mechanism Of Action
• Figure 4-5: Columvi - Mechanism Of Action
• Figure 4-6: Epkinly - Mechanism Of Action
• Figure 4-7: Talvey - Mechanism Of Action
• Figure 4-8: Elrexfio - Mechanism Of Action
• Figure 4-9: Imdelltra - Mechanism Of Action
• Figure 4-10: Ivonescimab - Mechanism Of Action
• Figure 4-11: Ziihera - Mechanism Of Action
• Figure 4-12: Lynozyfic - Mechanism Of Action
• Figure 4-13: Regulatory Designations - Benefits
• Figure 5-1: Multiclonics - Distinctive Characteristics
• Figure 5-2: Biclonics - Format
• Figure 5-3: ADAPTIR Bispecific Structure
• Figure 5-4: ADAPTIR-FLEX
• Figure 5-5: BEAT Platform - Multispecific Antibodies
• Figure 5-6: FIT-Ig - Proprietary Bispecific Platform
• Figure 5-7: BiClone format
• Figure 5-8: BioAtla CABs - Features
• Figure 5-9: BioAtla CABs - Benefits
• Figure 5-10: IMBiologic Bispecific Antibodies - Strategy
• Figure 5-11: IMBiologic Bispecific Antibodies - Mechanism Of Action
• Figure 5-12: Novel HBICE
• Figure 5-13: HBICE - Mechanism Of Action 1
• Figure 5-14: HBICE - Mechanism Of Action 2
• Figure 5-15: Phanes Therapeutics - PACbody Platform
• Figure 5-16: Phanes Therapeutics - SPECpair Platform
• Figure 5-17: Phanes Therapeutics - ATACCbody
• Figure 5-18: Numab Therapeutics - Technology
• Figure 5-19: Grabody I Platform - Mechanism Of Action
• Figure 5-20: Grabody I Platform - Mechanism Of Action
• Figure 5-21: 3-Step DuoBody Production Process
• Figure 5-22: DuoHexaBody Molecules - Schematic
• Figure 5-23: iTAb - Patented Structure
• Figure 5-24: iTAb - Mechanism of Action
• Figure 5-25: Synimmune - Proprietary Bispecific Antibody Format
• Figure 5-26: BiTE - Structure
• Figure 5-27: BiTE Molecule
• Figure 5-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
• Figure 5-29: ALiCE - Characteristics
• Figure 5-30: ALiCE - Schematic Diagram & Mechanism Of Action
• Figure 5-31: Abz2 Bispecific Platform
• Figure 5-32: Abz2 Bispecifics - Benefits
• Figure 5-33: Neo-X-Prime Bispecific Mechanism
• Figure 5-34: B-Body Bispecific Antibody - Structre
• Figure 5-35: xLinkBsAb - Structure
• Figure 5-36: PrecisionGATE Bispecific Antibody - Structure
• Figure 6-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2025
• Figure 6-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2025
• Figure 6-3: Global - Bispecific Antibodies Market Shares By Drugs (%), 2025
• Figure 6-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2025
• Figure 6-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2025
• Figure 6-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
• Figure 6-7: US -Bispecific Antibody Market (US$ Million), 2020-2025
• Figure 6-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2025
• Figure 6-9: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2025
• Figure 6-10: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2025
• Figure 6-11: Blincyto - Total Treatment Cost & Reimbursement Cost
• Figure 6-12: Blincyto - In Pocket & Out of Pocket Cost of Treatment
• Figure 6-13: Hemlibra - Total Treatment Cost & Reimbursement Cost
• Figure 6-14: Hemlibra - In Pocket & Out Of Pocket Cost Of Treatment
• Figure 6-15: Rybrevant - Maximum Coverage By Medicaid (US$)
• Figure 6-16: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$)
• Figure 6-17: Vabysmo - Total Treatment Cost & Reimbursement Cost
• Figure 6-18: Vabysmo - In Pocket & Out Of Pocket Cost Of Treatment
• Figure 6-19: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2026 - 2031
• Figure 7-1: US - Bispecific Antibodies Approval
• Figure 8-1: Blincyto - Approval Year By Region
• Figure 8-2: Blincyto - Patent Filing & Expiration Year
• Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
• Figure 8-4: Blincyto - Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
• Figure 8-5: Blincyto - Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
• Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
• Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2025
• Figure 8-8: Global - Blincyto Quaterly Sales (US$ Million), 2025
• Figure 8-9: US - Blincyto Sales (US$ Million), 2020-2025
• Figure 8-10: US - Blincyto Quaterly Sales (US$ Million), 2025
• Figure 8-11: ROW - Blincyto Sales (US$ Million), 2020-2025
• Figure 8-12: ROW - Blincyto Quaterly Sales (US$ Million), 2025
• Figure 8-13: Hemlibra - Approval Years By Region
• Figure 8-14: Hemlibra - Cost Per Unit & Supply Of 30 mg/mL Subcutaneous Injection By Volume (US$), March'2026
• Figure 8-15: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2026
• Figure 8-16: Hemlibra - Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
• Figure 8-17: Global - Hemlibra Sales (US$ Million), 2020-2025
• Figure 8-18: Global - Hemlibra Quaterly Sales (US$ Million), 2025
• Figure 8-19: Global - US v/s ROW Sales (US$ Million), 2025
• Figure 8-20: Global - Hemlibra Sales By Region (US$ Million), 2025
• Figure 8-21: Global - Hemlibra Sales By Region (%), 2025
• Figure 8-22: US - Hemlibra Sales (US$ Million), 2020-2025
• Figure 8-23: US - Hemlibra Quaterly Sales (US$ Million), 2025
• Figure 8-24: Europe - Hemlibra Sales (US$ Million), 2020-2025
• Figure 8-25: Europe - Hemlibra Quaterly Sales (US$ Million), 2025
• Figure 8-26: Japan - Hemlibra Sales (US$ Million), 2020-2025
• Figure 8-27: Japan - Hemlibra Quaterly Sales (US$ Million), 2025
• Figure 8-28: ROW - Hemlibra Sales (US$ Million), 2020-2025
• Figure 8-29: ROW - Hemlibra Quaterly Sales (US$ Million), 2025
• Figure 8-30: Rybrevant - Patent Filing & Expiration Year
• Figure 8-31: Rybrevant - Price Per Unit & Supply Of Intravenous Solution (US$), March'2026
• Figure 8-32: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
• Figure 8-33: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
• Figure 8-34: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
• Figure 8-35: Global - Rybrevant Sales (US$ Million), 2024-2025
• Figure 8-36: Global - Rybrevant Quaterly Sales (US$ Million), 2025
• Figure 8-37: US - Rybrevant Sales ((US$ Million), 2024-2025
• Figure 8-38: US - Rybrevant Quaterly Sales (US$ Million), 2025
• Figure 8-39: ROW - Rybrevant Sales (US$ Million), 2024-2025
• Figure 8-40: ROW - Rybrevant Quaterly Sales (US$ Million), 2025
• Figure 8-41: Vabysmo - Approval Year By Region
• Figure 8-42: Rybrevant - Patent Filing & Expiration Year
• Figure 8-43: Vabysmo - Price Per Unit & Supply Of Intravitreal Solution (US$), March'2026
• Figure 8-44: Global - Vabysmo Sales (US$ Million), 2022-2025
• Figure 8-45: Global - Vabysmo Quaterly Sales (US$ Million), 2025
• Figure 8-46: Global - US v/s ROW Sales (US$ Million), 2025
• Figure 8-47: Global - Vabysmo Sales By Region (US$ Million), 2025
• Figure 8-48: Global - Vabysmo Sales By Region (%), 2025
• Figure 8-49: US - Vabysmo Sales (US$ Million), 2022-2025
• Figure 8-50: US - Vabysmo Quaterly Sales (US$ Million), 2025
• Figure 8-51: Europe - Vabysmo Sales (US$ Million), 2022-2025
• Figure 8-52: Europe - Vabysmo Quaterly Sales (US$ Million), 2025
• Figure 8-53: Japan - Vabysmo Sales (US$ Million), 2022-2025
• Figure 8-54: Japan - Vabysmo Quaterly Sales (US$ Million), 2025
• Figure 8-55: ROW - Vabysmo Sales (US$ Million), 2022-2025
• Figure 8-56: ROW - Vabysmo Quaterly Sales (US$ Million), 2025
• Figure 8-57: Lunsumio - Approval Years By Region
• Figure 8-58: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
• Figure 8-59: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
• Figure 8-60: Global - Lunsumio Sales (US$ Million), 2022-2025
• Figure 8-61: Global - Lunsumio Quaterly Sales (US$ Million), 2025
• Figure 8-62: Global - US v/s ROW Sales (US$ Million), 2025
• Figure 8-63: Global - Lunsumio Sales By Region (US$ Million), 2025
• Figure 8-64: Global - Lunsumio Sales By Region (%), 2025
• Figure 8-65: US - Lunsumio Sales (US$ Million), 2022-2025
• Figure 8-66: US - Lunsumio Quaterly Sales (US$ Million), 2025
• Figure 8-67: Europe - Lunsumio Sales (US$ Million), 2022-2025
• Figure 8-68: Europe - Lunsumio Quaterly Sales (US$ Million), 2025
• Figure 8-69: Japan - Lunsumio Sales (US$ Million), 2022-2025
• Figure 8-70: Japan - Lunsumio Quaterly Sales (US$ Million), 2025
• Figure 8-71: ROW - Lunsumio Sales (US$ Million), 2022-2025
• Figure 8-72: ROW - Lunsumio Quaterly Sales (US$ Million), 2025
• Figure 8-73: China - Kaitani Sales (US$ Million), 2022-2023
• Figure 8-74: Tecvayli - Approval Years by Region
• Figure 8-75: Tecvayli - Patent Acceptance & Expiration Year
• Figure 8-76: US - Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
• Figure 8-77: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
• Figure 8-78: Global - Tecvayli Sales (US$ Million), 2022-2025
• Figure 8-79: Tecvayli - US v/s ROW Sales (US$ Million), 2025
• Figure 8-80: Tecvayli - US v/s ROW Sales (%), 2025
• Figure 8-81: Global - Tecvayli Quaterly Sales (US$ Million), 2025
• Figure 8-82: US - Tecvayli Sales (US$ Million), 2022-2025
• Figure 8-83: US - Tecvayli Quaterly Sales (US$ Million), 2025
• Figure 8-84: ROW - Tecvayli Sales (US$ Million), 2022-2025
• Figure 8-85: ROW - Tecvayli Quaterly Sales (US$ Million), 2025
• Figure 8-86: Columvi - Approval Year By Region
• Figure 8-87: US - Price Per Unit & Supply Of Columvi Intravenous Solution (US$), March'2026
• Figure 8-88: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March'2026
• Figure 8-89: Global - Columvi Sales (US$ Million), 2023-2025
• Figure 8-90: Global - Columvi Quaterly Sales (US$ Million), 2025
• Figure 8-91: Global - US v/s ROW Sales (US$ Million), 2025
• Figure 8-92: Global - Columvi Sales By Region (US$ Million), 2025
• Figure 8-93: Global - Columvi Sales By Region (%), 2025
• Figure 8-94: US - Columvi Sales (US$ Million), 2023-2025
• Figure 8-95: US - Columvi Quaterly Sales (US$ Million), 2025
• Figure 8-96: Europe - Columvi Sales (US$ Million), 2023-2025
• Figure 8-97: Europe - Columvi Quaterly Sales (US$ Million), 2025
• Figure 8-98: ROW - Columvi Sales (US$ Million), 2023-2025
• Figure 8-99: ROW - Columvi Quaterly Sales (US$ Million), 2025
• Figure 8-100: Epkinly - Approval Year By Region
• Figure 8-101: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), March'2026
• Figure 8-102: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March'2026
• Figure 8-103: Global - Epkinly Sales (US$ Million), 2023-2025
• Figure 8-104: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023-2025
• Figure 8-105: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023-2025
• Figure 8-106: Global - Epkinly Quaterly Sales (US$ Million), 2025
• Figure 8-107: Talvey - Approval Year By Region
• Figure 8-108: Talquetamab - FDA & EMA Designation Year
• Figure 8-109: Talvey - Patent Acceptance & Expiration Year
• Figure 8-110: US - Price Per Unit & Supply Of Talvey Intravenous Solution (US$), March'2026
• Figure 8-111: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March'2026
• Figure 8-112: Global - Talvey Sales (US$ Million), 2024-2025
• Figure 8-113: Global - Talvey Quaterly Sales (US$ Million), 2025
• Figure 8-114: US - Talvey Sales ((US$ Million), 2024-2025
• Figure 8-115: US - Talvey Quaterly Sales (US$ Million), 2025
• Figure 8-116: ROW - Talvey Sales (US$ Million), 2024-2025
• Figure 8-117: ROW - Talvey Quaterly Sales (US$ Million), 2025
• Figure 8-118: Elrexfio - Approval Year by Region
• Figure 8-119: Elranatamab - FDA & EMA Designation Year
• Figure 8-120: US - Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), March'2026
• Figure 8-121: Global - Elrexfio Sales (US$ Million), 2023-2025
• Figure 8-122: Global - Elrexfio Quaterly Sales (US$ Million), 2025
• Figure 8-123: US - Elrexfio Sales (US$ Million), 2023-2025
• Figure 8-124: Global - Elrexfio Quaterly Sales (US$ Million), 2025
• Figure 8-125: ROW - Elrexfio Sales (US$ Million), 2023-2025
• Figure 8-126: Global - Elrexfio Quaterly Sales (US$ Million), 2025
• Figure 8-127: Imdelltra - Approval Year By Region
• Figure 8-128: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
• Figure 8-129: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
• Figure 8-130: Global - Imdelltra Sales (US$ Million), 2024-2025
• Figure 8-131: Global - Imdelltra Quaterly Sales (US$ Million), 2025
• Figure 8-132: US - Imdelltra Sales ((US$ Million), 2024-2025
• Figure 8-133: US - Imdelltra Quaterly Sales (US$ Million), 2025
• Figure 8-134: ROW - Imdelltra Sales (US$ Million), 2024-2025
• Figure 8-135: ROW - Imdelltra Quaterly Sales (US$ Million), 2025
• Figure 8-136: EU - Price Of Supply Of Ordspono Intravenous Powder (US$), March'2026
• Figure 8-137: US & EU - Price Per Unit & Supply Of Ziihera (US$), March'2026
• Figure 8-138: Global - Ziihera Sales (US$ Million), 2024-2025
• Figure 8-139: Global - Ziihera Quaterly Sales (US$ Million), 2025
• Figure 8-140: Zenocutuzumab - Active Patents
• Figure 8-141: US - Price Of Supply Of Bizengri Intravenous Solution (US$), March'2026
• Figure 8-142: US - Price Per Unit & Supply of Lynozyfic Intravenous Solution, March'2026
• Figure 9-1: Global - Number of Bispecific Antibodies In Clinical Pipeline By Phase, 2026 Till 2031
• Figure 11-1: MK-1045-002 Phase I/II Study (NCT05579132) - Initiation & Completion Year
• Figure 11-2: LINKER-MM1 Phase I/II Study (NCT03761108) - Initiation & Completion Year
• Figure 11-3: LBL-034-CN001 Phase I/II Study (NCT06049290) - Initiation & Completion Year
• Figure 11-4: LINKER-SMM1 Phase II Study (NCT05955508) - Initiation & Completion Year
• Figure 11-5: EPCORE FL-1 Phase III Study (NCT05409066) - Initiation & Completion Year
• Figure 11-6: EPCORE(TM) NHL-2 Phase I/II Study (NCT04663347) - Initiation & Completion Year
• Figure 11-7: COALITION Phase I/II Study (NCT04914741) - Initiation & Completion Year
• Figure 11-8: ELM-2 Phase II Study (NCT03888105) - Initiation & Completion Year
• Figure 11-9: OLYMPIA-1 Phase III Study (NCT06091254) - Initiation & Completion Year
• Figure 11-10: OLYMPIA-2 Phase III Study (NCT06097364) - Initiation & Completion Year
• Figure 11-11: OLYMPIA-3 Phase III Study (NCT06091865) - Initiation & Completion Year
• Figure 11-12: OLYMPIA-4 Phase III Study (NCT06230224) - Initiation & Completion Year
• Figure 11-13: OLYMPIA-5 Phase III Study (NCT06149286) - Initiation & Completion Year
• Figure 11-14: HX009-I-01 Phase I Study (NCT05731752) - Initiation & Completion Year
• Figure 11-15: HX009-II-01 Phase I/II Study (NCT04886271) - Initiation & Completion Year
• Figure 11-16: DeLLphi-304 Phase III Study (NCT05740566) - Initiation & Completion Year
• Figure 11-17: HARMONi Phase III Study (NCT06396065) - Initiation & Completion Year
• Figure 11-18: HARMONi-6 Phase III Study (NCT05840016) - Initiation & Completion Year
• Figure 11-19: HERIZON-GEA-01 Phase III Study (NCT05152147) - Initiation & Completion Year
• Figure 11-20: eNRGy Phase II Study (NCT02912949) - Initiation & Completion Year
• Figure 11-21: AK104-303 Phase III Study (NCT02912949) - Initiation & Completion Year
• Figure 11-22: AK104-308 Phase II Study (NCT06371157) - Initiation & Completion Year
• Figure 11-23: TWINPEAK Phase I/II Study (NCT05482893) - Initiation & Completion Year
• Figure 11-24: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation & Completion Year
• Figure 11-25: CIBI389A101 Phase I Study (NCT02912949) - Initiation & Completion Year
• Figure 11-26: INCA 33890-101 Phase I Study (NCT05836324) - Initiation & Completion Year
• Figure 11-27: INCA033890-303 Phase III Study (NCT07284849) - Initiation & Completion Year
• Figure 11-28: COMPANION-002 Phase II/III Study (NCT05506943) - Initiation & Completion Year
• Figure 11-29: BNT327-02 Phase II Study (NCT06449222) - Initiation & Completion Year
• Figure 11-30: RNDO-564-001 Phase I Study (NCT07218003) - Initiation & Completion Year
• Figure 11-31: LBL-033-CN001 Phase I/II Study (NCT05779163) - Initiation & Completion Year
• Figure 11-32: NAV-240-201 Phase II Study (NCT07384975) - Initiation & Completion Year
• Figure 11-33: ZL-1503-001 Phase I Study (NCT07235384) - Initiation & Completion Year
• Figure 11-34: FRONTIER 4 Phase III Study (NCT05685238) - Initiation & Completion Year
• Figure 11-35: NXTAGE Phase I/II Study (NCT05987449) - Initiation & Completion Year
• Figure 11-36: HMB-001-CL101 Phase II Study (NCT06211634) - Initiation & Completion Year
• Figure 11-37: PEAK Phase III Study (NCT06990399) - Initiation & Completion Year
• Figure 11-38: PINNACLE Phase III Study (NCT06996080) - Initiation & Completion Year
• Figure 11-39: RV584 Phase I Study (NCT05890963) - Initiation & Completion Year
• Figure 11-40: 001965-I Phase I Study (NCT06585891) - Initiation & Completion Year

List of Tables

• Table 3-1: Clinically Approved Bispecific Antibody Combinations
• Table 3-2: Bispecific Antibody & Chemotherapy Combinations In Clinical Trials
• Table 3-3: Bispecific Antibody & Targeted Therapy Combinations In Clinical Trials
• Table 3-4: Bispecific Antibody & Immunotherapy Combinations In Clinical Trials
• Table 3-5: Bispecific Antibody & Radiotherapy Combinations In Clinical Trials
• Table 4-1: Approved Bispecific Antibodies
• Table 4-2: US - Bispecific Antibodies With Regulatory Designations
• Table 4-3: EU - Bispecific Antibodies With Regulatory Designations
• Table 4-4: China - Bispecific Antibodies with Regulatory Designations
• Table 6-1: Epkinly - Billing Unit Application For Doses
• Table 6-2: Talvey - Coverage Summary
• Table 6-3: Talvey - Coding Summary
• Table 6-4: Elrexfio - HCPCS Codes
• Table 6-5: Elrexfio - HCPCS Modifiers
• Table 6-6: Imdelltra - Payer Coverage & Reimbursement Details
• Table 6-7: Ziihera - ICD-10-CM Codes
• Table 6-8: Ziihera - ICD-10-PCS Codes
• Table 6-9: LYNOZYFIC - HCPCS code
• Table 8-1: Blincyto - Active Patents
• Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
• Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
• Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
• Table 8-5: Rybrevant - Premedication
• Table 8-6: Rybrevant - Dose Reductions For Adverse Reactions
• Table 8-7: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
• Table 8-8: Lunsumio - Recommended Treatment Cycles
• Table 8-9: Lunsumio - Recommended Premedications
• Table 8-10: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
• Table 8-11: Tecvayli - Dosing Schedule
• Table 8-12: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
• Table 8-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
• Table 8-14: Columvi - Premedications To Be Administered
• Table 8-15: Columvi - Recommendations For Management Of Cytokine Release Syndrome
• Table 8-16: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
• Table 8-17: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
• Table 8-18: Epkinly - Dosage Schedule
• Table 8-19: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
• Table 8-20: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
• Table 8-21: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
• Table 8-22: Talvey - Weekly Dosing Schedule
• Table 8-23: Talvey - Biweekly Dosing Schedule
• Table 8-24: Talvey - Recommendations For Management of CRS
• Table 8-25: Talvey - Recommendations For Management Of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
• Table 8-26: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
• Table 8-27: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
• Table 8-28: Elrexfio - Dosing Schedule
• Table 8-29: Elrexfio - Recommendations For Management Of CRS
• Table 8-30: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
• Table 8-31: Ordspono - Recommended Dose
• Table 8-32: Ordspono - Premedications & Post-Medications For Patients With r/r FL Or r/r DLBCL
• Table 8-33: Ordspono - Recommendations For Management Of Cytokine Release Syndrome
• Table 8-34: Ziihera - Dosage Modifications For Adverse Reactions
• Table 8-35: Bizengri - Premedications Prior To Infusions
• Table 8-36: Bizengri - Premedications Prior to Infusions
• Table 8-37: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
• Table 8-38: Korjuny - Dosing Schedule
• Table 8-39: Lynozyfic - Dosing Schedule
• Table 8-40: Lynozyfic - Recommendations for Restarting Therapy After a Dose Delay